Lezón C E, Martínez M P, Conti M I, Bozzini C E
Department of Physiology, University of Buenos Aires, Faculty of Odontology, Argentina.
Endocrine. 1998 Jun;8(3):331-3. doi: 10.1385/ENDO:8:3:331.
Erythropoietin (EPO) is a glycoprotein hormone produced primarily in the kidneys and to a lesser extent in the liver that regulates red cell production. Most of the studies conducted in experimental animals to assess the role of EPO in the regulation of erythropoiesis were performed in mouse models. However, little is known about the in vivo metabolism of the hormone in this species. The present study was thus undertaken to measure the plasma tl/2 of radiolabeled recombinant human EPO (rh-EPO) in normal mice as well as in mice with altered erythrocyte production rates (EPR), plasma EPO (pEPO) titer, marrow responsiveness, red cell volume, or liver function. Adult CF-1 mice of both sexes were used throughout. For the EPO life-span studies, 30 mice in each experiment were intravenously injected with 600,000 cpm of 125l-rh-EPO and bled by cardiac puncture in groups of five every hour for 6 h. Trichloroacetic acid (TCA) was added to each plasma sample and the radioactivity in the precipitate measured in a gamma-counter. EPO, pEPO, marrow responsiveness, or red cell volume were altered by either injections of rh-EPO, 5-fluorouracil, or phenylhydrazine, or by bleeding, or red cell transfusion. Liver function was altered by CI4C administration. In the normal groups of mice, the estimated tl/2 was 182.75+/-14.4 (SEM) min. The estimated tl/2 of the other experimental groups was not significantly different from normal. These results, therefore, strongly suggest that the clearance rate of EPO in mice is not subjected to physiologic regulation and that pEPO titer can be really taken as the reflection of the EPO production rate, at least in the experimental conditions reported here.
促红细胞生成素(EPO)是一种主要在肾脏产生、少量在肝脏产生的糖蛋白激素,它调节红细胞生成。大多数在实验动物中进行的评估EPO在红细胞生成调节中作用的研究是在小鼠模型中进行的。然而,对于该物种中这种激素的体内代谢知之甚少。因此,本研究旨在测量正常小鼠以及红细胞生成率(EPR)、血浆EPO(pEPO)滴度、骨髓反应性、红细胞体积或肝功能改变的小鼠中放射性标记的重组人EPO(rh-EPO)的血浆半衰期。实验全程使用成年CF-1雌雄小鼠。在EPO寿命研究中,每个实验的30只小鼠静脉注射600,000 cpm的125I-rh-EPO,每小时通过心脏穿刺对5只小鼠进行放血,共进行6小时。向每个血浆样本中加入三氯乙酸(TCA),并在γ计数器中测量沉淀物中的放射性。通过注射rh-EPO、5-氟尿嘧啶或苯肼,或放血或红细胞输血来改变EPO、pEPO、骨髓反应性或红细胞体积。通过给予CCl4来改变肝功能。在正常小鼠组中,估计的半衰期为182.75±14.4(SEM)分钟。其他实验组的估计半衰期与正常组无显著差异。因此,这些结果强烈表明,小鼠中EPO的清除率不受生理调节,并且pEPO滴度至少在此处报道的实验条件下可真正作为EPO产生率的反映。